knowledge -WSS

knowledge

author：explore 2025-09-06 05:03:26 - browse：865

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Listen: Wegovy in the brain & pivotal Alzheimer's data

WSS

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Key House panel plots a new health care package

Akili, maker of video game for ADHD, to be acquired for 34 million

AI used to predict Covid

Medicare to cover more brain scans for Alzheimer’s patients

hotspot

knowledge

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

At Orexo, a ‘turning point’ for everything but digital health

Bright Health sells Medicare Advantage business to Molina

Doctors find melanoma drugs effective against rare brain cancer

Wildfire smoke exposes gaps in outdoor worker protections

Addiction doctors spar with methadone clinics over legislation

Virginia high school admissions case could be legal follow

Stigma and the return of syphilis

Anesthesiologist group: stop taking Ozempic before surgery

AI can’t replace a physician’s gut feeling

knowledge

Biden tests positive for Covid

Sanders adds drug shortage policies to pandemic preparedness bill

Health insurers say they are turning to AI to cut costs, improve care

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

At Orexo, a ‘turning point’ for everything but digital health

hotspot

hotspot

explore

hotspot